Current drugs targeting metabolic conditions, such as sodium-glucose transport protein 2 (SGLT2) inhibitors or the glucagon-like peptide-1 receptor (GLP1R) agonists for diabetes, have also shown improvements in NAFLD patients [3,4], yet a lack of liver-specific pharmacological agents limits the effective management and treatment of fatty liver disease. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.